PHASE-I STUDY OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON)
- 1 January 1980
- journal article
- research article
- Vol. 64 (12) , 1247-1251
Abstract
A phase I study of 6-diazo-5-oxo-L-norleucine given i.v. on a twice weekly schedule was conducted. Twenty-six evaluable [cancer] patients received 31 courses of the drug. Doses ranged from 100-500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 i.v. twice weekly.This publication has 8 references indexed in Scilit:
- PHASE-II STUDY OF AZOTOMYCIN IN SARCOMAS1977
- IMAGING OF SPONTANEOUS CANINE TUMORS WITH AMMONIA AND L-GLUTAMINE LABELED WITH N-131977
- DON, CONV and DONV—III. Pharmacologic and toxicologic studiesBiochemical Pharmacology, 1976
- STUDIES ON MECHANISM OF INHIBITION OF TUMOR GROWTH BY ENZYME GLUTAMINASE1966
- GLUCOSAMINE METABOLISM .5. ENZYMATIC SYNTHESIS OF GLUCOSAMINE 6-PHOSPHATE1960
- Pharmacological and initial therapeutic observations on 6-Diazo-5-Oxo-L-Norleucine (Don) in human neoplastic diseaseCancer, 1957
- INVIVO SENSITIVITY OF NORMAL AND NEOPLASTIC MOUSE TISSUES TO AZASERINE1957
- The Glutamyltransferase Activity of Normal and Neoplastic TissuesJNCI Journal of the National Cancer Institute, 1954